{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:00:40Z","timestamp":1770480040075,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":2102,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1097\/jto.0b013e3181cee24f","type":"journal-article","created":{"date-parts":[[2010,2,18]],"date-time":"2010-02-18T07:11:05Z","timestamp":1266477065000},"page":"369-375","source":"Crossref","is-referenced-by-count":32,"title":["Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer"],"prefix":"10.1016","volume":"5","author":[{"given":"Alberto","family":"Chiappori","sequence":"first","affiliation":[]},{"given":"Gerold","family":"Bepler","sequence":"additional","affiliation":[]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[]},{"given":"Jean-Charles","family":"Soria","sequence":"additional","affiliation":[]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[]},{"given":"Alessandra","family":"Bearz","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Barata","sequence":"additional","affiliation":[]},{"given":"Giorgio","family":"Scagliotti","sequence":"additional","affiliation":[]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[]},{"given":"Asavari","family":"Wagle","sequence":"additional","affiliation":[]},{"given":"Astra M.","family":"Liepa","sequence":"additional","affiliation":[]},{"given":"Yan Daniel","family":"Zhao","sequence":"additional","affiliation":[]},{"given":"Nadia","family":"Chouaki","sequence":"additional","affiliation":[]},{"given":"Neill","family":"Iscoe","sequence":"additional","affiliation":[]},{"given":"Joachim","family":"von Pawel","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3181cee24f_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1634\/theoncologist.11-3-274","article-title":"Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC","volume":"11","author":"Maione","year":"2006","journal-title":"Oncologist"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib3","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1158\/0008-5472.CAN-05-0071","article-title":"The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts","volume":"65","author":"Graff","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib4","first-page":"780","article-title":"Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance","volume":"63","author":"Clark","year":"2003","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2559.2006.02461.x","article-title":"Immunohistochemical detection of protein kinase C-beta (PKC-beta) in tumour specimens of patients with non-small cell lung cancer","volume":"49","author":"Lahn","year":"2006","journal-title":"Histopathology"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib6","first-page":"381","article-title":"Protein kinase C-beta 2 inhibits cycling and decreases c-myc-induced apoptosis in small cell lung cancer cells","volume":"8","author":"Barr","year":"1997","journal-title":"Cell Growth Differ"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00408-004-0310-8","article-title":"Signaling pathways in NSCLC as a predictor of outcome and response to therapy","volume":"182","author":"Gupta","year":"2004","journal-title":"Lung"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2005.10.003","article-title":"Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis","volume":"51","author":"Tang","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib9","doi-asserted-by":"crossref","first-page":"45556","DOI":"10.1074\/jbc.M407701200","article-title":"Protein kinase C beta II regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo","volume":"279","author":"Liu","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00280-003-0713-x","article-title":"LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice","volume":"53","author":"Keyes","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib11","first-page":"73","article-title":"Enzastaurin (LY317615.HCl) suppresses signaling through the PKC and AKT pathways, inducing apoptosis, suppressing tumor-induced angiogenesis and reducing growth of human cancer xenografts","volume":"47","author":"McNulty","year":"2006","journal-title":"Proc Amer Assoc Cancer Res"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib12","doi-asserted-by":"crossref","first-page":"612s","DOI":"10.1200\/jco.2006.24.18_suppl.13138","article-title":"Enzastaurin a protein kinase Cbeta-selective inhibitor, inhibits the growth of SCLC and NSCLC cell lines","volume":"24","author":"Nakajima","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib13","unstructured":"Llombart-Cussac A, Matias-Guiu Guia X, Medina DM, et al. Enzastaurin inhibits in vivo GSK3\u03b2 phosphorylation in early breast cancer. Presented at the 100th Annual Meeting of the American Association for Cancer Research, Denver, CO, 2009 (abstract LB-256)."},{"key":"10.1097\/JTO.0b013e3181cee24f_bib14","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1200\/JCO.2005.05.3447","article-title":"Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer","volume":"24","author":"Carducci","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib15","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.2006.09.3146","article-title":"Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"25","author":"Robertson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib16","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1200\/JCO.2007.14.3685","article-title":"Enzastaurin, an oral serine\/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer","volume":"26","author":"Oh","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib17","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1200\/JCO.2005.02.477","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib18","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1200\/JCO.2007.12.3026","article-title":"Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer","volume":"25","author":"Herbst","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib19","doi-asserted-by":"crossref","first-page":"412s","DOI":"10.1200\/jco.2006.24.18_suppl.7194","article-title":"Sorafenib combined with carboplatin\/paclitaxel for advanced non-small cell lung cancer: a phase I subset analysis","volume":"24","author":"Schiller","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib20","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2008.20.8355","article-title":"Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study","volume":"27","author":"Schiller","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib21","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1158\/1078-0432.CCR-06-2912","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer","volume":"13","author":"Rademaker-Lakhai","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CAD.0b013e3282f077b3","article-title":"A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors","volume":"19","author":"Camidge","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib23","first-page":"603","article-title":"Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro","volume":"43","author":"Oberschmidt","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib24","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib25","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib26","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1093\/annonc\/mdp049","article-title":"Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced\/metastatic cancer","volume":"20","author":"Hanauske","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib28","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1158\/1078-0432.CCR-08-3071","article-title":"A phase I trial of enzastaurin in patients with recurrent gliomas","volume":"15","author":"Kreisl","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib29","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/1097-0142(19940415)73:8<2087::AID-CNCR2820730813>3.0.CO;2-X","article-title":"Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale","volume":"73","author":"Hollen","year":"1994","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/JTO.0b013e31815e8b48","article-title":"Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer","volume":"3","author":"de Marinis","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib31","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","article-title":"Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial","volume":"373","author":"Pirker","year":"2009","journal-title":"Lancet"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib32","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib33","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib34","doi-asserted-by":"crossref","first-page":"697s","DOI":"10.1200\/jco.2007.25.18_suppl.18163","article-title":"Phase II trial of bevacizumab plus pemetrexed and carboplatin in previously untreated advanced nonsquamous non-small cell lung cancer","volume":"25","author":"Dalsania","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib35","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2008.20.8181","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer","volume":"27","author":"Patel","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib36","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1158\/1078-0432.CCR-08-2031","article-title":"Randomized phase II designs","volume":"15","author":"Rubinstein","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2007.09.011","article-title":"Recommended changes to oncology clinical trial design: revolution or evolution?","volume":"44","author":"Ratain","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1740774507086648","article-title":"Interim futility analysis with intermediate endpoints","volume":"5","author":"Goldman","year":"2008","journal-title":"Clin Trials"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib39","doi-asserted-by":"crossref","first-page":"416s","DOI":"10.1200\/jco.2009.27.15_suppl.8037","article-title":"Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) + enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB\/IV non-small cell lung cancer (NSCLC)","volume":"27","author":"Obasaju","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib40","doi-asserted-by":"crossref","first-page":"415s","DOI":"10.1200\/jco.2009.27.15_suppl.8035","volume":"27","author":"Casey","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1634\/theoncologist.2008-0232","article-title":"The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies","volume":"14","author":"Scagliotti","year":"2009","journal-title":"Oncologist"},{"key":"10.1097\/JTO.0b013e3181cee24f_bib42","doi-asserted-by":"crossref","first-page":"806s","DOI":"10.1200\/jco.2009.27.18_suppl.cra8000","article-title":"Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC)","volume":"27","author":"Belani","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608641532311X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608641532311X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T06:23:11Z","timestamp":1634970191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155608641532311X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S155608641532311X"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3181cee24f","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}